Distinguished in Chronic B-Cell Leukemia (CBCL)

Michael Kneba

Kiel, SH, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Chronic B-Cell Leukemia (CBCL)
Kiel, SH, DE 
OverviewLocationsClinical Research

Overview

Michael Kneba practices in Kiel, Germany. Mr. Kneba is rated as a Distinguished expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 84 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 41 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Male

Locations

Kiel, SH, Germany
Other Locations
Koeln, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Enrollment Status: Recruiting
Publish Date: December 19, 2017
Intervention Type: Drug
Study Drugs: R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT Conditioning, Ibrutinib (Maintenance)
Study Phase: Phase 3
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
Enrollment Status: Unknown
Publish Date: April 27, 2023
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Bortezomib, Autologous Stem Cell Transplant, Aallogeneic Stem Cell Transplant
Study Phase: Phase 3
View 1 Less Clinical Trial

84 Total Publications

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 14, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kneba's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile